title: Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
abstract: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The development and progression of DN might involve multiple factors. Connective tissue growth factor (CCN2, originally known as CTGF) is the one which plays a pivotal role. Therefore, increasing attention is being paid to CCN2 as a potential therapeutic target for DN. Up to date, there are also many drugs or agents which have been shown for their protective effects against DN via different mechanisms. In this review, we only focus on the potential renoprotective therapeutic agents which can specifically abolish CCN2 expression or nonspecifically inhibit CCN2 expression for retarding the development and progression of DN.
authors.affiliation: Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China ; Department of Nephrology, Jilin Province People's Hospital, Changchun 130021, China.
authors.forename: Songyan
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Nephrology, Jilin Province People's Hospital, Changchun 130021, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Urology, The 2nd Hospital of Changchun, Changchun 130061, China.
authors.forename: Chunguang
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China.
authors.forename: Wenpeng
authors.initials: W
authors.lastname: Cui
authors.affiliation: Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China.
authors.forename: Lining
authors.initials: L
authors.lastname: Miao
mesh_terms: D000818:Animals; D000872:Anthocyanins / Q000737:chemistry; D000911:Antibodies, Monoclonal / Q000737:chemistry; D055513:Connective Tissue Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000378:metabolism*; D018450:Disease Progression; D000077270:Exenatide; D006146:Guanidines / Q000737:chemistry; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism; D007249:Inflammation; D007668:Kidney / Q000187:drug effects*; D007676:Kidney Failure, Chronic / Q000473:pathology; D051379:Mice; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D016376:Oligonucleotides, Antisense / Q000235:genetics; D010455:Peptides / Q000737:chemistry; D012084:Renin-Angiotensin System; D013148:Spironolactone / Q000737:chemistry; D014688:Venoms / Q000737:chemistry; D062367:ortho-Aminobenzoates / Q000737:chemistry; D054460:rho-Associated Kinases / Q000378:metabolism
chemical_list: D000872:Anthocyanins; D000911:Antibodies, Monoclonal; C526317:CCN2 protein, human; C526318:CCN2 protein, mouse; D006146:Guanidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016376:Oligonucleotides, Antisense; D010455:Peptides; D014688:Venoms; D062367:ortho-Aminobenzoates; D055513:Connective Tissue Growth Factor; D013148:Spironolactone; D000077270:Exenatide; D054460:rho-Associated Kinases; D009173:Mycophenolic Acid; C012293:tranilast; C004479:pimagedine